Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Vertex Pharmaceuticals Incorporated

Market Cap 111B 95.53B 87.87B 82.42B 154B 10,589B 157B 1,042B 405B 5,104B 415B 406B 17,694B P/E Ratio 2026 *
24.9x
P/E Ratio 2027 * 22.1x
Enterprise Value 97.8B 84.49B 77.71B 72.89B 137B 9,364B 139B 922B 359B 4,514B 367B 359B 15,648B EV / Sales 2026 *
7.5x
EV / Sales 2027 * 6.55x
Free-Float
99.8%
Yield 2026 *
-
Yield 2027 * -
1 day+2.14%
1 week+3.90%
Current month-0.56%
1 month+3.54%
3 months-10.84%
6 months+0.09%
Current year-1.84%
1 week 433.8
Extreme 433.8
453.16
1 month 420.01
Extreme 420.01
456.68
Current year 412.27
Extreme 412.27
507.92
1 year 362.5
Extreme 362.5
507.92
3 years 331.87
Extreme 331.87
519.88
5 years 176.36
Extreme 176.36
519.88
10 years 71.46
Extreme 71.46
519.88
Manager TitleAgeSince
Chief Executive Officer 53 2020-03-31
Director of Finance/CFO 58 2019-04-09
Chief Tech/Sci/R&D Officer - 2021-06-30
Director TitleAgeSince
Director/Board Member 66 1997-12-31
Chairman 70 2012-04-30
Director/Board Member 57 2015-06-17
Date Insider Type Main position Quantity % Market Cap.
Jun. 04Sell

Chief Technology Officer

-1,745 0.0007%
May. 31Sell

General Counsel

-828 0.0003%
May. 28Sell

Chief Technology Officer

-1,974 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+2.14%+3.90%-1.44%+33.20% 111B
+2.16%+7.62%+43.83%+160.28% 1,013B
-0.07%+6.76%+52.34%+48.95% 574B
-0.08%+3.52%+18.61%+62.66% 397B
+0.77%+4.97%+21.24%+15.95% 324B
+0.85%+2.79%+24.89%+15.93% 280B
+2.10%+7.06%+24.57%+34.79% 273B
+4.84%+4.68%+20.66%+61.85% 182B
-0.19%+3.96%-45.64%-48.23% 194B
+3.61%-2.42%+14.33%+61.12% 151B
Average +0.77%+2.55%+17.34%+44.65% 349.92B
Weighted average by Cap. +0.40%+3.92%+28.38%+71.26%

Financials

2026 *2027 *
Net sales 13.04B 11.26B 10.36B 9.72B 18.21B 1,248B 18.5B 123B 47.8B 602B 48.94B 47.89B 2,086B 14.27B 12.32B 11.34B 10.63B 19.93B 1,366B 20.24B 134B 52.31B 658B 53.56B 52.4B 2,283B
Net income 4.45B 3.85B 3.54B 3.32B 6.22B 426B 6.32B 41.96B 16.32B 205B 16.71B 16.35B 712B 5.05B 4.37B 4.02B 3.77B 7.06B 484B 7.17B 47.63B 18.53B 233B 18.97B 18.56B 808B
Net Debt -12.78B -11.04B -10.16B -9.53B -17.86B -1,224B -18.14B -121B -46.88B -590B -47.99B -46.96B -2,046B -17.13B -14.8B -13.62B -12.77B -23.94B -1,641B -24.31B -162B -62.82B -791B -64.32B -62.93B -2,741B
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
26-06-11 445.04 $ +2.14% 1,230,809
26-06-10 435.71 $ -2.26% 1,103,240
26-06-09 445.77 $ +0.63% 871,497
26-06-08 442.96 $ -0.87% 1,149,408
26-06-05 446.83 $ +1.15% 1,530,180
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
435.71USD
Average target price
548.69USD
Spread / Average Target
+25.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VRTX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!